Amgen (AMGN) Non-Current Deferred Tax Liability (2016 - 2025)
Historic Non-Current Deferred Tax Liability for Amgen (AMGN) over the last 12 years, with Q3 2025 value amounting to $1.5 billion.
- Amgen's Non-Current Deferred Tax Liability fell 1478.67% to $1.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 billion, marking a year-over-year decrease of 1478.67%. This contributed to the annual value of $1.6 billion for FY2024, which is 6066.21% down from last year.
- As of Q3 2025, Amgen's Non-Current Deferred Tax Liability stood at $1.5 billion, which was down 1478.67% from $1.4 billion recorded in Q2 2025.
- Over the past 5 years, Amgen's Non-Current Deferred Tax Liability peaked at $4.1 billion during Q4 2023, and registered a low of $1.4 billion during Q2 2025.
- In the last 4 years, Amgen's Non-Current Deferred Tax Liability had a median value of $1.7 billion in 2024 and averaged $1.9 billion.
- Per our database at Business Quant, Amgen's Non-Current Deferred Tax Liability soared by 11897.65% in 2023 and then plummeted by 6066.21% in 2024.
- Quarter analysis of 4 years shows Amgen's Non-Current Deferred Tax Liability stood at $1.9 billion in 2022, then soared by 118.98% to $4.1 billion in 2023, then plummeted by 60.66% to $1.6 billion in 2024, then decreased by 9.78% to $1.5 billion in 2025.
- Its Non-Current Deferred Tax Liability stands at $1.5 billion for Q3 2025, versus $1.4 billion for Q2 2025 and $1.5 billion for Q1 2025.